Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma
Open Access
Abstract
Gastric marginal zone lymphoma (gMZL) of mucosa-associated lymphoid tissue (MALT) may persist even after H. pylori eradication, or it can be primarily Helicobacter pylori (H. pylori) independent. For patients without the successful eradication of lymphoma, or with progressive disease, treatment options have historically included partial or total gastrectomy. Presently, in these instances, curative radiation therapy (RT) is the current standard of care. This review emphasizes the historically changing role of radiation therapy in gMZL, progressing from large-volume RT without surgery, to localized RT, on its own, as a curative organ-preserving treatment. This overview shows the substantial progress in radiation therapy during the recent two to three decades, from high-dose, large-field techniques to low-dose, localized target volumes based on advanced imaging, three-dimensional treatment planning, and advanced treatment delivery techniques. RT has evolved from very large extended field techniques (EF) with prophylactic treatment of the whole abdomen and the supradiaphragmatic lymph nodes, applying doses between 30 and 50 Gy, to involved-field RT (IF), to the current internationally recommended involved site radiation therapy (ISRT) with a radiation dose of 24–30 Gy in gMZL. Stage-adapted RT is a highly effective and safe treatment with excellent overall survival rates and very rare acute or late treatment-related toxicities, as shown not only in retrospective studies, but also in large prospective multicenter studies, such as those conducted by the German Study Group on Gastrointestinal Lymphoma (DSGL). Further de-escalation of the radiation treatments with low-dose 20 Gy, as well as ultra-low-dose 4 Gy radiation therapy, is under investigation within ongoing prospective clinical trials of the International Lymphoma Radiation Oncology Group (ILROG) and of the German Lymphoma Alliance (GLA).Keywords
This publication has 114 references indexed in Scilit:
- Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphomaWorld Journal of Gastroenterology, 2013
- Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric studyRadiation Oncology, 2012
- Second Malignant Neoplasms and Cardiovascular Disease Following RadiotherapyJNCI: Journal of the National Cancer Institute, 2012
- Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphomaCancer Letters, 2011
- Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide studyEuropean Journal of Cancer, 2008
- Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphomaAnnals of Oncology, 2008
- Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series: Figure 1Gut, 2007
- Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patientsEuropean Journal of Cancer, 2005
- Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical OutcomeJournal of Clinical Oncology, 2003
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993